EUVIMEDEUVIMED entdecken
Crossref

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC

Insu Kim, Sun Ha Choi, Shin Yup Lee, Seung Soo Yoo, Ji Eun Park, Kyeong-Cheol Shin, Jong Geol Jang, Kyung Soo Hong, Yong Shik Kwon, Sun Hyo Park, Keum-Ju Choi, Chi Young Jung und 8 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.17279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Insu Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, B7-H1 Antigen, Lung Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsB7-H1 AntigenLung NeoplasmsAntibodies, MonoclonalBiomarkers, TumorMutationNeoplasm StagingHumansFemaleMaleAgedMiddle AgedAdultAged, 80 and overAntineoplastic Agents, ImmunologicalProgression-Free SurvivalRetrospective Studies

Stichwörter der Autor:innen

EGFRNSCLCPD-L1durvalumab

Substanzen

durvalumabErbB ReceptorsB7-H1 AntigenCD274 protein, humanAntibodies, MonoclonalEGFR protein, humanBiomarkers, TumorAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
  • Department of Internal Medicine, School of Medicine, Keimyung University, Busan, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Daegu Catholic University, Daegu, Republic of Korea.
  • Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Republic of Korea.

Zitieren

APA

Kim, I., Choi, S. H., Lee, S. Y., Yoo, S. S., Park, J. E., Shin, K. C., Jang, J. G., Hong, K. S., Kwon, Y. S., Park, S. H., Choi, K. J., Jung, C. Y., Kim, M. H., Kim, S. H., Seol, H. Y., Kim, J., Park, J. H., Kim, T. H., Eom, J. S., & Ahn, J. H. (2024). PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC. Anticancer Research. https://doi.org/10.21873/anticanres.17279

Vancouver

Kim I, Choi SH, Lee SY, Yoo SS, Park JE, Shin KC, et al. PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC. Anticancer Research. 2024. doi:10.21873/anticanres.17279

BibTeX
@article{Kim2024,
  author = {Kim, Insu and Choi, Sun Ha and Lee, Shin Yup and Yoo, Seung Soo and Park, Ji Eun and Shin, Kyeong-Cheol and Jang, Jong Geol and Hong, Kyung Soo and Kwon, Yong Shik and Park, Sun Hyo and Choi, Keum-Ju and Jung, Chi Young and Kim, Mi-Hyun and Kim, Soo Han and Seol, Hee Yun and Kim, Jehun and Park, Jin-Han and Kim, Tae Hoon and Eom, Jung Seop and Ahn, June Hong},
  title = {PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17279}
}
Kostenlos starten →